Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPY2R | P49146 | 5/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ME2 | P23368 | 7/20 | 0.45 |
| ▸ | ME1 | P48163 | 7/20 | 0.45 |
| ▸ | ME3 | Q16798 | 7/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26550578 | 0.90 | NPY2R (0.49) | OPRD1ALDH1A1MAPTNPY2RHTR1D | |
| SCHEMBL31287348 | 0.84 | NPY2R (0.47) | OPRD1ALDH1A1MAPTNPY2RGAA | |
| SCHEMBL23033248 | 0.83 | MAPT (0.46) | OPRD1ALDH1A1MAPTPKMKDM4E | |
| SCHEMBL31287363 | 0.82 | NPY2R (0.48) | OPRD1ALDH1A1NPY2RHTR1DHTR1B | |
| SCHEMBL31287366 | 0.82 | NPY2R (0.67) | OPRD1ALDH1A1MAPTPKMKDM4E | |
| SCHEMBL15417704 | 0.79 | LMNA (0.50) | OPRD1ALDH1A1MAPTPKMKDM4E | |
| SCHEMBL13115170 | 0.78 | DGAT1 (0.52) | OPRD1ALDH1A1MAPTKDM4ENPY2R | |
| SCHEMBL31287364 | 0.77 | NPY2R (0.43) | NPY2RHTR1DHTR1B | |
| SCHEMBL31287362 | 0.77 | OGA (0.45) | NPY2RHTR1DHTR1B | |
| SCHEMBL31287355 | 0.76 | OPRD1 (0.59) | OPRD1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3706727-B1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | ACELOT INC (US) | 2024-07-31 | — | — | EP | claimed |
| EP-4417596-B1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A-BETA-42 OLIGOMER FORMATION | ACELOT INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12318357-B2 | Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12312296-B2 | Substituted piperazines as disrupters of AB42 oligomer formation | ACELOT, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4417596-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | Acelot, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-3706727-B1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | ACELOT INC (US) | 2024-07-31 | — | — | EP | disclosed |
| JP-2024079840-A | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO Aβ42 OLIGOMER FORMATION | エースロット，インコーポレイテッド | 2024-06-11 | — | — | JP | disclosed |
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | ACELOT, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230331658-A1 | Small Molecule Drugs and Related Methods for Treatment of Diseases Related to Abeta42 Oligomer Formation | ACELOT, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331658-A1 | Small Molecule Drugs and Related Methods for Treatment of Diseases Related to Abeta42 Oligomer Formation | ACELOT, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-3993781-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO TDP-43, ALPHA-SYNUCLEIN, HUNTINGTIN'S PROTEIN AND TAU PROTEIN OLIGOMER FORMATION | Acelot, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | ACELOT,INC (US) | 2021-02-25 | — | — | US | disclosed |
| WO-2021025723-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO TDP-43, ALPHA-SYNUCLEIN, HUNTINGTIN'S PROTEIN AND TAU PROTEIN OLIGOMER FORMATION | ACELOT, INC. (US) | 2021-02-11 | — | — | WO | disclosed |
| EP-3706727-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO A 42 OLIGOMER FORMATION | Acelot, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | ACELOT, INC. | 2020-07-16 | — | — | US | disclosed |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | ACELOT, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | ACELOT, INC. | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210959-A1 | Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation | APP, PSEN2, PSEN1 | OPRD1 3885/4885ALDH1A1 4713/4885MAPT 6/4885 |
| US-10703711-B2 | Small molecule drugs and related methods for treatment of diseases related to Aβ42 oligomer formation | APP, PSEN2, PSEN1 | OPRD1 3619/4885ALDH1A1 4482/4885MAPT 5/4885 |
| US-20230331658-A1 | Small Molecule Drugs and Related Methods for Treatment of Diseases Related to Abeta42 Oligomer Formation | APP, PSEN2, PSEN1 | OPRD1 3885/4885ALDH1A1 4713/4885MAPT 6/4885 |
| US-11827582-B2 | Substituted amines as disrupters of ABETA42 oligomer formation | APP, PSEN2, BACE1 | OPRD1 3698/4885ALDH1A1 4062/4885MAPT 7/4885 |
| US-20200223788-A1 | SMALL MOLECULE DRUGS AND RELATED METHODS FOR TREATMENT OF DISEASES RELATED TO ABETA42 OLIGOMER FORMATION | APP, PSEN2, PSEN1 | OPRD1 3885/4885ALDH1A1 4713/4885MAPT 6/4885 |
| US-12318357-B2 | Small molecule drugs and related methods for treatment of diseases related to TDP-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | OPRD1 1071/4885ALDH1A1 4583/4885MAPT 4/4885 |
| US-20210052519-A1 | Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation | HTT, TARDBP, SNCA | OPRD1 1174/4885ALDH1A1 4676/4885MAPT 4/4885 |
| US-12312296-B2 | Substituted piperazines as disrupters of AB42 oligomer formation | APP, PSEN2, SEC62 | OPRD1 3028/4885ALDH1A1 1583/4885MAPT 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.